Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774204 | 0.86 | ALDH1A1 (0.43) | PDE10AJAK2KDM4ENPC1MAPK1 | |
| SCHEMBL5777127 | 0.86 | KMT2A (0.44) | PDE10AJAK2HSP90AB1KDM4ENPC1 | |
| SCHEMBL5777168 | 0.85 | KDM4E (0.49) | KDM4EKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL5774575 | 0.84 | FYN (0.41) | PDE10AJAK2HSP90AB1KDM4EHSD17B10 | |
| SCHEMBL2144889 | 0.80 | PDPK1 (0.50) | PDPK1PDE10AJAK2NUDT1HSP90AB1 | |
| SCHEMBL4066707 | 0.76 | PDE10A (0.45) | PDE10AJAK2HSP90AB1KDM4EMAPK1 | |
| SCHEMBL21886983 | 0.73 | JAK2 (0.47) | PDPK1JAK2NUDT1KDM4EHSD17B10 | |
| SCHEMBL2250839 | 0.71 | PDE4D (0.64) | PDPK1PDE10AJAK2NUDT1HSP90AB1 | |
| SCHEMBL5770812 | 0.69 | MAPT (0.48) | JAK2KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL2144884 | 0.67 | NUDT1 (0.58) | PDPK1NUDT1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436292-B1 | 5-METHOXY-8-ARYL-¬1,2,4|TRIAZOLO¬1,5-A|PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-08-30 | — | — | EP | disclosed |
| EP-1436292-A1 | 5-METHOXY-8-ARYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6693116-B2 | 8-PHENYL-(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030134873-A1 | Adenosine receptor ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | disclosed |
| WO-2003031445-A1 | 5-METHOXY-8-ARYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134873-A1 | Adenosine receptor ligands | ADORA1, ADORA2A, ADORA3 | PDPK1 2126/4885PDE10A 903/4885JAK2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.